PeptiDream Inc (4587)

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.